What Mydocalm-Richter Treats: Main Uses and Benefits

---

The medication is commonly used to provide symptomatic relief in conditions where heightened muscle tone and intense pain interfere with daily functioning. The active ingredient is relevant across domains where short-term symptom management is appropriate. It is applied in addressing pathologically increased tone of the skeletal muscles (spasticity), often following a cerebral stroke, and acute, painful muscle spasms associated with conditions of the spine, such as acute low back pain or cervical syndromes.

The medication provides supportive relief of both the intense muscle contraction and the localized sensory discomfort, which may assist with maintaining functional stability and comfort during symptomatic episodes.

“The application of this medication is relevant for easing the functional strain and stiffness that characterize acute muscular rigidity.”

Easing Acute, Severe Muscle Spasms and Localized Pain

This medication is applied in situations involving acute, high-degree muscle stiffness and the associated severe musculoskeletal pain. The medication is used to provide supportive relief during episodes of sudden symptom escalation.

Support for Pathological Muscle Hypertonicity (Spasticity)

Mydocalm-Richter is relevant in clinical settings involving sustained muscle rigidity. In situations involving this muscle rigidity, the medication helps to ease functional strain and supports patients in rehabilitation efforts.

---

Quick Fact: Relief for Acute Muscle Tension The medication is commonly used to help with severe musculoskeletal pain and the accompanying high-degree muscle stiffness.

Regulatory References

1. European Medicines Agency (EMA) overview on Tolperisone

Mydocalm-Richter's eligibility is strictly defined by regulatory guidance, limiting its use based on its formulation and patient health status.

General Eligibility Restrictions

The injectable formulation is not recommended for continued use in the European Union, following a determination by the European Medicines Agency (EMA) that the benefits do not outweigh the identified risks for this specific route of administration.

Absolute Contraindications

Use is contraindicated in patients with a diagnosis of Myasthenia gravis or a known history of hypersensitivity (allergy) to Tolperisone, Lidocaine, or other amide-type local anesthetics. The medicine is also prohibited for individuals with severe cardiac conduction disorders, such as all grades of atrioventricular block.

Population and Conditional Restrictions

• Age: Use is generally not recommended for children or adolescents under 18 due to limited safety data; the primary component is restricted to adults.
• Physiological States: The medicine should not be used by women who are pregnant or breastfeeding due to a lack of established safety data.
• Organ Function: Eligibility is conditional: patients with moderate hepatic or renal impairment require mandated dose reductions and close monitoring as specified in the official prescribing information.

Interactions with other medicines and products

The official regulatory profile for Mydocalm-Richter (Tolperisone/Lidocaine) details two main categories of interactions, primarily related to the active ingredient, Tolperisone. These interaction statements are based strictly on standard government-approved product information.

---

Pharmacokinetic Interactions (Exposure Modification)

Co-administration may result in an increase in the plasma concentration of medicinal products that are metabolized predominantly by the enzyme CYP2D6. This pharmacokinetic interaction is documented to affect the exposure of the co-administered drug. Specific medicines officially listed as being affected include certain beta-blockers, such as Metoprolol and Nebivolol, as well as other agents like Thioridazine, Venlafaxine, and Tolterodine.

---

Pharmacodynamic Interactions (Additive Effects)

The drug is associated with additive effects when administered with specific substance categories. Co-administration with other centrally acting muscle relaxants, benzodiazepines, or nonsteroidal anti-inflammatory drugs (NSAIDs) may result in a combined pharmacological response. This documented effect may necessitate a dose reduction of one or both medicinal products. Furthermore, the official labeling notes the potential for an additive central nervous system (CNS) depressant effect when taken with alcohol.

No combinations are formally classified as contraindicated due to interaction risk in the primary regulatory text, and no explicit timing separation rules are documented.

How Mydocalm-Richter Works

The biological action of the drug is exerted through two distinct mechanistic domains that modulate electrical signaling in the nervous system at different anatomical locations.

Central Modulation of Motor Neuron Excitability

This domain, driven primarily by Tolperisone, involves the central modulation of motor neuron excitability within the spinal cord and brainstem. Tolperisone works by inhibiting both voltage-gated sodium ( Nav) and specific N-type calcium ( Cav) channels. This dual channel blockade stabilizes the neuronal membranes, depressing the activity of spinal reflex arcs and reducing the Ca^2+ influx necessary for releasing excitatory neurotransmitters. The mechanism produces a central physiological consequence of decreased skeletal muscle hypertonus. The mechanism of action is characterized by a specific profile that does not rely on generalized central nervous system depression.

Peripheral Cessation of Sensory Signal Transmission

This domain is mediated by Lidocaine, which exerts its action locally at the administration site via rapid physiological modulation. Lidocaine is a membrane-stabilizing agent that directly and immediately blocks voltage-gated sodium channels ( Nav) on peripheral sensory nerve fibers. This action halts the generation and propagation of electrical impulses along afferent nerves, resulting in the localized cessation of sensory signal transmission. This mechanism results in a rapid, regional modulation of nerve activity, while the action of Tolperisone modulates central motor pathway hyperexcitability.

How to Use Mydocalm-Richter

The usage of Mydocalm-Richter solution for injection is defined by therapeutic guidelines, which govern its administration route, dosage, and frequency.

---

Administration Scope

Feature	Guideline
Route of Administration	The preparation is designated for Intramuscular (IM) injection and is administered by a qualified healthcare professional.
Standard Dosing Schedule	The typical dose is one ampoule per administration, containing 100 mg of Tolperisone Hydrochloride and 2.5 mg of Lidocaine Hydrochloride. The total daily dose usually does not exceed two ampoules.
Frequency Pattern	The medication is typically administered twice daily (BID) as an acute treatment course.
Special Procedural Conditions	The injection must be administered slowly. Dosage adjustment is necessary for patients with moderate hepatic or renal impairment; use is generally restricted in severe cases.
Age-Group Rules	The injection is not recommended for use in individuals under 18 years of age.

---

Use Protocol and Constraints

The administration of Mydocalm-Richter is primarily intended for short-term, initial management of acute symptoms, with a procedural expectation to transition to oral medication as soon as clinically feasible.

A key constraint notes that the injectable formulation is not authorized for use in the European Union (EU), based on the established balance of benefits and identified risks for this specific form. The overall regimen is defined by the requirement for professional supervision and adherence to the IM administration route.

Research Evidence / Overview of Studies for Mydocalm-Richter

This overview provides a summary of the types of clinical studies that have been conducted for Mydocalm-Richter (Tolperisone), describing what researchers studied and the current limitations of the available data, without offering medical advice or treatment recommendations.

---

Evidence for Use in Pathological Muscle Tone (Spasticity)

Research exploring spasticity, a condition characterized by rigid and involuntary muscle stiffness, includes trials of various designs, such as randomized, double-blind, placebo-controlled studies. These studies primarily examined adults presenting with spasticity related to neurological conditions, such as post-stroke recovery. Researchers monitored outcomes related to physical discomfort, assessing muscle tone with the Ashworth Scale and changes in functional performance. The evidence base is largely derived from a limited number of central studies that were submitted to regulatory bodies.

---

Evidence for Use in Acute Muscle Spasm and Pain

For research exploring acute muscle spasms and resulting physical discomfort, the evidence includes short-term, randomized, placebo-controlled trials (Phase 2 and 3). These studies focused on episodes of heightened symptoms, such as acute low back pain, in adults. Key outcomes monitored included changes in subjective pain scores (using the NRS) and improvements in functional mobility, typically over a short follow-up duration of 7 to 14 days.

---

Evidence in Special Populations

Research has explored the medicine's use in distinct groups, including children who experience muscle rigidity associated with neurological disorders and older adults in the context of acute muscle spasm trials. However, data for certain subgroups remain insufficient, and findings related to these populations are uncertain.

---

What is Still Uncertain About Mydocalm-Richter Research

Several research limitation frames apply to the existing evidence. The most notable uncertainty is the extremely limited official data available for the Mydocalm-Richter injectable combination product. The quality of evidence also varies across studies, as older research methods are not fully aligned with current standards. Long-term effects for both main indications are not fully established, and regulatory assessments have indicated that evidence derived from some older studies, which examined non-spasticity indications, was historically unconvincing.

Key Studies & References

1. Lidocaine Injection - MedlinePlus Drug Information

Common questions about Mydocalm-Richter (FAQ)

Q: What is Mydocalm-Richter and how does it work?

Mydocalm-Richter is a brand name for the active substance tolperisone hydrochloride, which belongs to a group of medicines called centrally acting muscle relaxants.

It works on the central nervous system (brain and spinal cord) to block certain nerve signals that cause muscles to tighten or become stiff. By reducing this nerve signaling, tolperisone helps to decrease excessive muscle tone and relieve muscle spasms and the associated pain.

---

Q: What conditions is Mydocalm-Richter used to treat?

Mydocalm-Richter is primarily used to treat the increased tone of skeletal muscles (muscle spasticity) that results from neurological disorders, such as damage to the tracts of the central nervous system.

Examples of such conditions include:

• Stroke
• Multiple sclerosis
• Spinal cord damage

It may also be used to treat other conditions where muscle spasms and stiffness are present, such as in certain diseases of the musculoskeletal system, on the advice of a physician.

---

Q: What are the common side effects of Mydocalm-Richter?

Like all medicines, Mydocalm-Richter can cause side effects, although not everyone gets them.

Common side effects (may affect up to 1 in 10 people) include:

• Muscle weakness (asthenia)
• Headache
• Dizziness
• Nausea and stomach discomfort (dyspepsia)

Less common side effects (may affect up to 1 in 100 people) include:

• Sleep disorders (insomnia)
• Allergic skin reactions, such as itching or rash (urticaria)
• Low blood pressure (hypotension)

If you experience any signs of a severe allergic reaction (such as swelling of the face, lips, tongue, or throat, or difficulty breathing), you must stop taking the medicine and seek immediate medical attention.

---

Q: Can I take Mydocalm-Richter with other medications?

Before starting Mydocalm-Richter, it is important to inform your doctor or pharmacist about all the medicines you are currently taking, including prescription and non-prescription medicines, vitamins, and herbal supplements.

Tolperisone, the active ingredient, may interact with other medicines, potentially changing their effects or increasing the risk of side effects.

Specific attention should be given if you are taking:

• Other centrally acting muscle relaxants
• Certain medicines that can increase the concentration of tolperisone in the blood, such as fluvoxamine
• Medicines for blood pressure (antihypertensives), as tolperisone may cause a drop in blood pressure

Your healthcare provider can assess potential interactions and adjust your treatment plan if necessary.

---

Q: Should Mydocalm-Richter be taken with food?

Yes, Mydocalm-Richter is generally recommended to be taken after a meal.

Studies have shown that taking the medicine after food significantly increases the absorption of the active substance, tolperisone, into the body. This improved absorption helps the medicine work more effectively. Taking it without food may lead to lower drug levels in the body, which could reduce its effectiveness.

Official Storage and Disposal Requirements

Mydocalm-Richter (Tolperisone and Lidocaine solution for injection) must be stored and handled according to strict regulatory guidelines to maintain its stability and ensure safety.

Storage Condition	Official Regulatory Requirement
Temperature	Store below 25 C (77 F) and do not freeze.
Protection	Keep ampoules in the original outer carton to protect the contents from light.
Stability/Use	Solution must be used immediately after opening the ampoule; discard any unused remainder.
Child Safety	Mandatory to keep this medicine out of the sight and reach of children.
Disposal	Dispose of unused product and waste material in accordance with local requirements, and do not throw away via wastewater or household waste.